Department for Physical Chemistry, Institute of Nuclear Sciences "Vinča" National Institute for the Republic of Serbia, University of Belgrade, Belgrade, Beograd, Serbia
Mr. David Piric
Department for Physical Chemistry, Institute of Nuclear Sciences "Vinča" National Institute for the Republic of Serbia, University of Belgrade, Belgrade, Beograd, Serbia
Diffuse large B-cell lymphoma (DLBCL) is a malignancy of immense biological and clinical heterogeneity. Based on the transcriptomic or genomic approach, several different classification schemes have evolved over the years to subdivide DLBCL into clinically (prognostically) relevant subsets, but each leaves unclassified samples. Herein, we outline the DLBCL tumor biology behind the actual and potential drug targets and address the challenges and drawbacks coupled with their (potential) use. Therapeutic modalities are discussed, including small-molecule inhibitors, naked antibodies, antibody–drug conjugates, chimeric antigen receptors, bispecific antibodies and T-cell engagers, and immune checkpoint inhibitors. Candidate drugs explored in ongoing clinical trials are coupled with diverse toxicity issues and refractoriness to drugs. According to the literature on DLBCL, the promise for new therapeutic targets lies in epigenetic alterations, B-cell receptor and NF-κB pathways. Herein, we present putative targets hiding in lipid pathways, ferroptosis, and the gut microbiome that could be used in addition to immuno-chemotherapy to improve the general health status of DLBCL patients, thus increasing the chance of being cured. It may be time to devote more effort to exploring DLBCL metabolism to discover novel druggable targets. We also performed a bibliometric and knowledge-map analysis of the literature on DLBCL published from 2014–2023.
Lipidome dysregulation is a hallmark of cancer and inflammation. The global plasma lipidome and sub-lipidome of inflammatory pathways have not been reported in diffuse large B-cell lymphoma (DLBCL). In a pilot study of plasma lipid variation in female DLBCL patients and BMI-matched disease-free controls, we performed targeted lipidomics using LC-MRM to quantify lipid mediators of inflammation and immunity, and those known or hypothesised to be involved in cancer progression: sphingolipids, resolvin D1, arachidonic acid (AA)-derived oxylipins, such as hydroxyeicosatetraenoic acids (HETEs) and dihydroxyeicosatrienoic acids, along with their membrane structural precursors. We report on the role of the eicosanoids in the separation of DLBCL from controls, along with lysophosphatidylinositol LPI 20:4, implying notable changes in lipid metabolic and/or signalling pathways, particularly pertaining to AA lipoxygenase pathway and glycerophospholipid remodelling in the cell membrane. We suggest here the set of S1P, SM 36:1, SM 34:1 and PI 34:1 as DLBCL lipid signatures which could serve as a basis for the prospective validation in larger DLBCL cohorts. Additionally, untargeted lipidomics indicates a substantial change in the overall lipid metabolism in DLBCL. The plasma lipid profiling of DLBCL patients helps to better understand the specific lipid dysregulations and pathways in this cancer.
Herein we present the analysis and comparing fundamental chemometric methods: fold change (FC) analysis and univariate statistics for identifying differentially expressed lipids in human serum samples into pancreatic cancer or control group, using a lipidomic datasets retrieved from the research article „Lipidomic profiling of human serum enables detection of pancreatic cancer“ by Wolrab et al. [1]. Our main objective was to assess and compare basic chemometric methods, as well as the potential using a smaller number of samples in lipidomic studies. We have concluded that it is possible to use a smaller number of samples for basic chemometric analysis, but the exact number depends on the level of accuracy required.
Herein we present the performance of three supervised machine learning (ML) algorithms: random forests (RF), extreme gradient boosting (XGB) and support vector machines (SVM) in classification of human serum samples into pancreatic cancer or control group, using a lipidomic dataset retrieved from the research article „Lipidomic profiling of human serum enables detection of pancreatic cancer“ by Wolrab et al. [1]. Our main objective was to assess and compare, for the three ML techniques, the performance metrics, that is accuracy, precision, sensitivity, F1 score and ROC- AUC, with those computed by decision trees (DT), which is the basis of RF and XGB algorithms, and commonly used partial least squares – discriminant analysis (PLS-DA) and orthogonal projections to latent structures – discriminant analysis (OPLS-DA). We suggest that RF, XGB and SVM represent excellent binary classifiers, making these three promising candidates for future use in the discovery of potential lipid biomarkers.
Herein we present the potential of four machine learning (ML) algorithms: Partial Least Squares – Discriminant Analysis (PLS-DA), Random Forests (RF), Support Vector Machines (SVM) and Decision Trees (DT) to classify human plasma samples into cancer or control group, using a lipidomic dataset retrieved from the research article „Lipidomic profiling of human serum enables detection of pancreatic cancer“ by Wolrab et al. [1]. Our main objective was to assess and compare, for the four ML techniques, the performance metrics, that is accuracy, precision, sensitivity, F1 score and ROC-AUC, with those computed by Orthogonal Projections to Latent Structures (OPLS)-DA in [1]. Our findings suggest that SVM and RF offer a superior performance as binary classifiers, making these two promising candidates for future use in the discovery of potential lipidomic biomarkers.